

Cynthia Behling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11166791/publications.pdf>

Version: 2024-02-01

55
papers

14,818
citations

147801

31
h-index

168389

53
g-index

58
all docs

58
docs citations

58
times ranked

16453
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and validation of a histological scoring system for nonalcoholic fatty liver disease. <i>Hepatology</i> , 2005, 41, 1313-1321.	7.3	8,518
2	Prevalence of Fatty Liver in Children and Adolescents. <i>Pediatrics</i> , 2006, 118, 1388-1393.	2.1	1,264
3	Histopathology of pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2005, 42, 641-649.	7.3	675
4	Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. <i>Journal of Pediatrics</i> , 2003, 143, 500-505.	1.8	446
5	Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. <i>New England Journal of Medicine</i> , 2021, 385, 1559-1569.	27.0	406
6	Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study. <i>Hepatology</i> , 2014, 60, 1920-1928.	7.3	388
7	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2019, 2, e1912565.	5.9	230
8	Pediatric Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2006, 43, 413-427.	1.8	214
9	Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019, 157, 1109-1122.	1.3	184
10	Prevalence of Prediabetes and Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease. <i>JAMA Pediatrics</i> , 2016, 170, e161971.	6.2	178
11	EUS-guided FNA diagnostic yield of malignancy in solid pancreatic masses: a benchmark for quality performance measurement. <i>Gastrointestinal Endoscopy</i> , 2007, 66, 277-282.	1.0	156
12	Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. <i>Hepatology</i> , 2013, 58, 1644-1654.	7.3	146
13	Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1877-1885.e5.	4.4	145
14	Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015, 61, 1887-1895.	7.3	138
15	Morbidity, Mortality, and Placental Pathology in Excessively Long Umbilical Cords: Retrospective Study. <i>Pediatric and Developmental Pathology</i> , 2001, 4, 144-153.	1.0	117
16	Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 307-310.e2.	1.3	113
17	Evidence and Recommendations for Imaging Liver Fat in Children, Based on Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 765-773.	4.4	106
18	Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017, 66, 1474-1485.	7.3	103

#	ARTICLE	IF	CITATIONS
19	Histologic Evaluation of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 564-575.	1.9	102
20	In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. <i>Gastroenterology</i> , 2016, 151, 1141-1154.e9.	1.3	100
21	Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children. <i>Journal of Pediatrics</i> , 2017, 187, 141-146.e1.	1.8	91
22	Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1513-1520.e1.	4.4	85
23	Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. <i>Hepatology</i> , 2020, 72, 1219-1229.	7.3	79
24	MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Gut</i> , 2021, 70, 1946-1953.	12.1	78
25	Longitudinal Assessment of High Blood Pressure in Children with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e112569.	2.5	75
26	Reproducibility of histological assessments of disease activity in UC. <i>Gut</i> , 2015, 64, 1765-1773.	12.1	66
27	Associations between histologic features of nonalcoholic fatty liver disease (NAFLD) and quantitative diffusion-weighted MRI measurements in adults. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 1629-1638.	3.4	57
28	Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 849-860.	7.3	57
29	In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 438-446.e1.	4.4	56
30	Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. <i>Gastroenterology</i> , 2020, 159, 1731-1751.e10.	1.3	49
31	Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. <i>Gut</i> , 2022, 71, 983-990.	12.1	45
32	Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2021, 73, 937-951.	7.3	32
33	Misuse of scoring systems. <i>Hepatology</i> , 2011, 54, 369-370.	7.3	29
34	Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Hepatology</i> , 2022, 75, 661-672.	7.3	29
35	Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 1456-1466.	3.4	28
36	Liver histology and diffusion-weighted MRI in children with nonalcoholic fatty liver disease: A MAGNET study. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1149-1158.	3.4	25

#	ARTICLE	IF	CITATIONS
37	Sex Hormone Relations to Histologic Severity of Pediatric Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3496-3504.	3.6	25
38	Parathyroid Hormone-related Protein as a Novel Tumor Marker in Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2002, 24, 284-290.	1.1	23
39	Validation of the accuracy of the FAST [®] score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. <i>PLoS ONE</i> , 2022, 17, e0266859.	2.5	20
40	Human Pancreatic Adenocarcinomas Express Parathyroid Hormone-Related Protein1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 310-316.	3.6	17
41	A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. <i>Hepatology Communications</i> , 2019, 3, 1571-1584.	4.3	16
42	Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110504.	3.2	15
43	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	7.3	15
44	Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019, 157, 1448-1456.e1.	1.3	11
45	Hepatic Nuclear Receptor Expression Associates with Features of Histology in Pediatric Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2018, 2, 1213-1226.	4.3	10
46	Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 380-387.e3.	4.4	10
47	Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2673-2674.e3.	4.4	9
48	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<sc>NAFLD</sc>). <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1441-1451.	3.7	9
49	Nonalcoholic fatty liver disease risk and histologic severity are associated with genetic polymorphisms in children. <i>Hepatology</i> , 2023, 77, 197-212.	7.3	8
50	Comparison of the Toxicities of Two Iron Formulations in a Swine Model. <i>Academic Emergency Medicine</i> , 1999, 6, 1104-1108.	1.8	6
51	Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-11.	1.2	6
52	Incidence of Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1261-1270.	4.4	5
53	Exome sequencing of an adolescent with nonalcoholic fatty liver disease identifies a clinically actionable case of Wilson disease. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a003087.	1.2	3
54	EUS-FNA Cytology: Material Preparation and Interpretation. , 0, , 57-62.		0

#	ARTICLE	IF	CITATIONS
55	Letter: noninvasive prediction models to exclude cirrhosis in <sc>NAFLD</sc> â€” not everyone fits the mould. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 182-183.	3.7	0